Tailored, Interactive Texts Boost Vaping Cessation Rates in Teens
By Lori Solomon HealthDay Reporter
TUESDAY, Aug. 13, 2024 -- A tailored, interactive text message intervention can increase self-reported nicotine vaping cessation rates among adolescents, according to a study published online Aug. 7 in the Journal of the American Medical Association.
Amanda L. Graham, Ph.D., from the Truth Initiative in Washington, D.C., and colleagues evaluated the effectiveness of a text message program for nicotine vaping cessation among adolescents. The analysis included 759 U.S. adolescents (13 to 17 years) randomly assigned to receive an automated, interactive text message program for vaping cessation that delivered cognitive and behavioral coping skills training and social support, as well as 744 assigned to monthly assessments only.
The researchers found that at the seven-month follow-up (70.8 percent), the point-prevalence abstinence rates were 37.8 percent among intervention participants and 28.0 percent among control participants (relative risk, 1.35). The treatment-outcome relationship was not mediated by any baseline variables. Among the adolescents who quit vaping, there was no evidence of transition to combustible tobacco products.
"Placing information about the intervention in clinics and waiting rooms may encourage intervention use among those who do not disclose their vaping," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-14 03:15
Read more
- Fish Oil Supplements Might Help Prevent Cancer
- ACG: Fewer Overt Hepatic Encephalopathy Episodes Seen With Rifaximin
- Study Identifies Risk Factors Associated With Severe Stroke
- Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
- Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
- July 2019 to June 2023 Saw Increase in OD Deaths With Ketamine Detected
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions